TAF13: A Protein as A Drug Target and Biomarker (G6884)

Target Name: TAF13

NCBI ID: G6884

TAF13

TAF13: A Protein as A Drug Target and Biomarker

TAF13 (MRT60) is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, and gastrointestinal tract. It is a member of the intermediate filament protein family, which is a family of transmembrane proteins that play a crucial role in cell-cell adhesion, migration, and invasion.

TAF13 is one of the key proteins that is targeted by small molecules, such as drugs, in order to treat various diseases. For example, TAF13 has been shown to be a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons for TAF13's potential as a drug target is its unique structure. TAF13 is a transmembrane protein that consists of an extracellular region, a transmembrane region, and an intracellular region. The extracellular region of TAF13 contains a unique domain that is composed of a repeated sequence of amino acids that is similar to that of the protein p120. The transmembrane region of TAF13 contains a protein that is similar to that of the tyrosine kinase family, and the intracellular region contains a unique domain that is composed of a repeated sequence of amino acids that is similar to that of the protein Myc.

The unique structure of TAF13 makes it an attractive target for small molecules. By modifying the structure of TAF13, researchers can disrupt its function and study its role in various diseases. This can be done through various methods, such as introducing small molecules that bind to specific residues on TAF13, or by using techniques such as RNA interference or CRISPR/Cas9 to knockdown or activate specific genes that are expressed in TAF13.

TAF13 has also been shown to be a potential biomarker for several diseases. For example, TAF13 has been used as a biomarker for cancer, as it has been shown to be overexpressed in various types of cancer. Additionally, TAF13 has been used as a biomarker for neurodegenerative diseases, as it has been shown to be expressed in the brains of individuals with Alzheimer's disease and other forms of neurodegenerative disease.

In addition to its potential as a drug target and biomarker, TAF13 is also of interest to researchers because of its unique function in various physiological processes. For example, TAF13 is involved in cell-cell adhesion and migration, which are important processes that are critical for the development and progression of many diseases. Additionally, TAF13 is involved in the regulation of the cytoskeleton, which is important for the structure and function of cells.

In conclusion, TAF13 is a protein that is of interest to researchers due to its unique structure and function. Its potential as a drug target and biomarker make it an attractive target for small molecules, and its role in various physiological processes makes it an important player in the study of diseases. Further research is needed to fully understand the functions of TAF13 and its potential as a therapeutic agent.

Protein Name: TATA-box Binding Protein Associated Factor 13

Functions: The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473, PubMed:9695952). TFIID recognizes and binds promoters via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473). TAF13, together with TAF11 and TBP, play key roles during promoter binding by the TFIID and TFIIA transcription factor complexes (PubMed:33795473)

The "TAF13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAF13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets